Newbury Pharmaceuticals AB (FRA:P52) Other Current Receivables: €2.47 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:P52 Newbury Pharmaceuticals AB FRA:P52
41 GF Score
Price €0.16
GF Value €0.20
! 6 Warning Signs
View Full Analysis

What is Newbury Pharmaceuticals AB Other Current Receivables?

Newbury Pharmaceuticals AB FRA:P52 -10.37% 41 Other Current Receivables is €2.47 Mil as of Feb. 2026. GuruFocus rates FRA:P52 with a GF Score™ of 41/100 and a GF Value™ of €0.20. The stock has 6 warning signs investors should review.

Newbury Pharmaceuticals AB's Other Current Receivables for the quarter that ended in Feb. 2026 was €2.47 Mil.

Newbury Pharmaceuticals AB's quarterly Other Current Receivables increased from Aug. 2025 (€1.42 Mil) to Nov. 2025 (€2.60 Mil) but then stayed the same from Nov. 2025 (€2.60 Mil) to Feb. 2026 (€2.47 Mil).

Newbury Pharmaceuticals AB's annual Other Current Receivables increased from Aug. 2023 (€0.63 Mil) to Aug. 2024 (€0.74 Mil) and increased from Aug. 2024 (€0.74 Mil) to Aug. 2025 (€1.42 Mil).

Newbury Pharmaceuticals AB Other Current Receivables Related Terms

Newbury Pharmaceuticals AB Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Newbury Pharmaceuticals AB's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB Other Current Receivables Chart

Newbury Pharmaceuticals AB Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Other Current Receivables
0.15 0.13 0.63 0.74 1.42

Newbury Pharmaceuticals AB Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.87 2.35 1.42 2.60 2.47
FRA:P52
41GF Score
Newbury Pharmaceuticals AB FRA:P52
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newbury Pharmaceuticals AB Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €2.47 Mil mean?
Newbury Pharmaceuticals AB (FRA:P52) has a Other Current Receivables of €2.47 Mil as of Feb. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Newbury Pharmaceuticals AB and its competitors.
Is Newbury Pharmaceuticals AB's Other Current Receivables too high?
Newbury Pharmaceuticals AB's current Other Current Receivables is €2.47 Mil. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Other Current Receivables compare to ZTS and UTHR?
Newbury Pharmaceuticals AB's Other Current Receivables of €2.47 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Newbury Pharmaceuticals AB and its competitors. Newbury Pharmaceuticals AB's current Other Current Receivables is €2.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current Other Current Receivables of €2.47 Mil. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current Other Current Receivables is €2.47 Mil. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current Other Current Receivables is €2.47 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?

Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued. The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.

Key valuation signals for FRA:P52:

  • Other Current Receivables: €2.47 Mil
  • GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newbury Pharmaceuticals AB Business Description

Other Exchanges NEWBRY:Sweden
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score

Get the complete analysis for FRA:P52

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.20
GF Value